a company called alivecor is upset because apple made a watch that can take your heart's picture. alivecor thinks they should get money because apple used their idea. but, a big group called us customs said apple didn't break any rules. so, apple can still make and sell these watches. this is good for apple, but it's not so good for alivecor. now, alivecor is trying to fix things in a special court, but it's a hard fight for them. Read from source...

Apple Watch's redesigned ECG isn't infringing on AliveCor patents, US Customs rules. This ruling further complicates the legal challenges that AliveCor has against Apple Inc. It seems that the US Customs and Border Protection has concluded that the Apple Watch's redesigned ECG does not violate the patents held by AliveCor. This means that Apple can import these specific Apple Watch models into the US for sale without having to pay a $2 bond for each unit. This is a significant win for Apple and adds to AliveCor's legal setbacks in its ongoing legal battle against Apple. It appears that AliveCor is currently appealing an antitrust case it lost in California. Moreover, the US Patent Trial and Appeal Board previously ruled that three of AliveCor's patents covering heart monitoring technologies for wearable devices are unpatentable. Overall, the legal battle between AliveCor and Apple has seen many twists and turns, with various outcomes favoring one company or the other. However, with this new ruling by the US Customs and Border Protection, it seems that Apple has come out on top in this particular instance.

Neutral.

The article discusses a legal case involving Apple and a medical device company called AliveCor, with the focus being on the recent ruling by US Customs and Border Protection that the redesigned ECG in the Apple Watch does not violate patents held by AliveCor. The sentiment here is neutral because the article presents information on an ongoing legal dispute without expressing any positive or negative view on the matter.

In light of the U.S. Customs and Border Protection's ruling that the redesigned Electrocardiography (ECG) feature in Apple Watch models does not violate patents held by AliveCor, it is evident that there is a degree of stability in the relationship between the two companies. This decision nullifies the Limited Exclusion Order that previously prevented Apple from importing these models into the U.S. market. However, this is not to say that the conflict between Apple and AliveCor is entirely resolved, as AliveCor continues to appeal an antitrust case it lost in California. Additionally, the U.S. Patent Trial and Appeal Board has previously ruled that three of AliveCor's patents related to heart monitoring technologies for wearable devices are unpatentable.

The current situation is conducive to further investment in Apple Watch, given the legal setbacks faced by AliveCor. Therefore, investors can consider purchasing shares in Apple (AAPL) as it appears to be benefiting from this situation. Moreover, Apple's recent move to disable the blood oxygen monitoring feature in its latest smartwatches due to patent disputes may indicate an underlying tension between Apple and medical device companies. This could also open up potential investment opportunities in companies that are not involved in such disputes. However, it would be advisable for investors to carefully monitor the developments in the ongoing legal battle between Apple and AliveCor, as further twists and turns could impact the market.